Prelude Therapeutics IncPRLDEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
PRLD Q3 FY2025 Key Financial Metrics
Revenue
$6.5M
Gross Profit
N/A
Operating Profit
$-20.4M
Net Profit
$-19.7M
Gross Margin
N/A
Operating Margin
-314.1%
Net Margin
-303.5%
YoY Growth
116.7%
EPS
$-0.26
Prelude Therapeutics Inc Q3 FY2025 Financial Summary
Prelude Therapeutics Inc reported revenue of $6.5M (up 116.7% YoY) for Q3 FY2025, with a net profit of $-19.7M (up 38.9% YoY) (-303.5% margin).
Key Financial Metrics
| Total Revenue | $6.5M |
|---|---|
| Net Profit | $-19.7M |
| Gross Margin | N/A |
| Operating Margin | -314.1% |
| Report Period | Q3 FY2025 |
Prelude Therapeutics Inc Quarterly Revenue & Net Profit History
Prelude Therapeutics Inc results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $6.5M | +116.7% | $-19.7M | -303.5% |
| Q3 FY2024 | $3.0M | — | $-32.3M | -1075.7% |
Income Statement
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Revenue | $3.0M | $6.5M |
| YoY Growth | N/A | 116.7% |
Balance Sheet
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Assets | $197.2M | $94.8M |
| Liabilities | $40.8M | $36.2M |
| Equity | $156.4M | $58.5M |
Cash Flow
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Operating CF | $-27.3M | $-19.1M |